CompletedNCT00206570
Estradiol added to antipsychotic treatment for schizophrenia in women
About this title
Read the official source — NCT00206570Medication studyAges 18–45Australia
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- MelbourneSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJanuary 2001
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Bayside Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Australia
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT00206570
- Official title
Show the full official title
Double Blind Study of Estradiol Plus Neuroleptic Versus Placebo Plus Neuroleptic in the Treatment of Psychotic Symptoms in Women With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Melbourne
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Bayside Health.
Did this study involve medication?
Yes. The study involved medication, including Estradiol.
Who was this study for?
Listed age limits: 18 years to 45 years.
